In this proposal, the interactions of PTH and ovarian hormones in the regulation of bone metabolism will be investigated. Women with endometriosis will be treated with a long-acting GnRH analog (Synarel) to produce a reversible state of severe estrogen deficiency that mimics the menopause. Although Synarel is highly effective as a therapy for endometriosis, its clinical usage is limited because of estrogen deficiency bone loss. In pilot study of 20 women, hPTH-(l-34) administration prevented trabecular bone loss from the spine in women treated with Synarel for 6 mo. No cortical bone loss was observed in either group. However, some prior data have suggested that cortical bone loss in elderly osteoporotic women might be accelerated after 9 mo of PTH therapy. Therefore, an additional l2 young women were treated with Synarel +/- hPTH-(l-34) for l2 mo. Trabecular bone loss was again prevented by PTH. More important, cortical bone mass was completely stable in both groups. A principal aim of this proposal is to determine whether hPTH-(l- 34) administration can prevent both cortical and trabecular bone loss in young, estrogen-deficient women. To do so, the study group must be sufficiently large and the study of sufficient duration to produce cortical bone loss in the women who receive Synarel alone. Other principal aims of this proposal are to investigate the mechanisms of PTH action on bone and of hypogonadal bone loss. 48 ovulatory women with endometriosis will be randomly assigned to treatment with Synarel alone or Synarel plus daily hPTH-(l-34) for l yr. Bone density of the lumbar spine (AP and lateral), femoral neck, trochanter, 1/3 radius, and total body bone mineral will be measured every 3 mo by DEXA to assess both cortical and trabecuLar bone. Serial measurements of calcium regulatory hormones, biochemical markers of bone turnover, and calcium absorption will be made to assess the mechanism of PTH action on bone. The patients who receive Synarel alone will be further randomized to undergo either l) iv calcium and citrate infusions before and at the end of Synarel therapy to assess the effects of chronic estrogen deficiency on the regulation of PTH secretion by calcium, or 2) 24 hr iv PTH infusions before and at the end of Synarel therapy to assess the effects of chronic estrogen deficiency on the ability of PTH to stimulate bone resorption and l ,25-(OH)2 vitamin D secretion. These investigations should help determine whether alterations in the secretion of PTH, skeletal sensitivity to PTH, or the ability of PTH to stimulate 1,25-(OH)2 vitamin D secretion and calcium absorption are involved in the mechanism of hypogonadal bone loss. Similar studies in a group of 24 normal women with regular menstrual cycles will be performed to document that women with endometriosis have normal baseline bone densities, biochemical markers of bone turnover, and regulation of PTH and l ,25-(OH)2 vitamin D secretion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29DK043341-04
Application #
2458776
Study Section
General Medicine B Study Section (GMB)
Program Officer
Margolis, Ronald N
Project Start
1994-08-01
Project End
1999-07-31
Budget Start
1997-08-01
Budget End
1998-07-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Ruan, Ye Chun; Wang, Yan; Da Silva, Nicolas et al. (2014) CFTR interacts with ZO-1 to regulate tight junction assembly and epithelial differentiation through the ZONAB pathway. J Cell Sci 127:4396-408
Shum, Winnie W C; Hill, Eric; Brown, Dennis et al. (2013) Plasticity of basal cells during postnatal development in the rat epididymis. Reproduction 146:455-69
Roy, Jeremy W; Hill, Eric; Ruan, Ye Chun et al. (2013) Circulating aldosterone induces the apical accumulation of the proton pumping V-ATPase and increases proton secretion in clear cells in the caput epididymis. Am J Physiol Cell Physiol 305:C436-46
Feinstein, Timothy N; Yui, Naofumi; Webber, Matthew J et al. (2013) Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J Biol Chem 288:27849-60
Vedovelli, Luca; Rothermel, John T; Finberg, Karin E et al. (2013) Altered V-ATPase expression in renal intercalated cells isolated from B1 subunit-deficient mice by fluorescence-activated cell sorting. Am J Physiol Renal Physiol 304:F522-32
P?unescu, Teodor G; Rodriguez, Steven; Benz, Eric et al. (2012) Loss of the V-ATPase B1 subunit isoform expressed in non-neuronal cells of the mouse olfactory epithelium impairs olfactory function. PLoS One 7:e45395
Ruan, Ye Chun; Shum, Winnie W C; Belleannée, Clémence et al. (2012) ATP secretion in the male reproductive tract: essential role of CFTR. J Physiol 590:4209-22
Bouley, Richard; Lu, Hua A J; Nunes, Paula et al. (2011) Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J Am Soc Nephrol 22:59-72
P?unescu, Teodor G; Ljubojevic, Marija; Russo, Leileata M et al. (2010) cAMP stimulates apical V-ATPase accumulation, microvillar elongation, and proton extrusion in kidney collecting duct A-intercalated cells. Am J Physiol Renal Physiol 298:F643-54
Miranda, Kevin C; Bond, Daniel T; McKee, Mary et al. (2010) Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int 78:191-9

Showing the most recent 10 out of 35 publications